Top

Exploring the correlation between Tom1L1 and the efficacy of neoadjuvant chemotherapy for locally progressive mid-low rectal cancer

Journals by subject

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio.

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer.

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe.

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area.

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

BMC Cancer

Published in:

Open Access 01-12-2024 | Rectal Cancer | Research

Exploring the correlation between Tom1L1 and the efficacy of neoadjuvant chemotherapy for locally progressive mid-low rectal cancer

Authors: Meng Li, Zeyu Li, Xueliang Wu, Yubo Pan, Likun Wang, Jun Xue, Tian Li

Published in: BMC Cancer | Issue 1/2024

Abstract

Objective

To investigate the specificity of Target of Myb1-Like1 (Tom1L1) expression in colorectal adenocarcinoma tissues and analyze the predictive value of Tom1L1 in the efficacy of neoadjuvant chemotherapy for patients with rectal adenocarcinoma.

Methods

The cancerous tissues and paracancerous normal tissues of 102 patients diagnosed with colorectal adenocarcinoma without treatment were selected; quantitative polymerase chain reaction (qPCR), Western blot and immunohistochemistry (IHC) were adopted to validate the expression level of Tom1L1 in the two groups. Furthermore, 34 patients with locally progressive mid-low rectal adenocarcinoma, who were treated with neoadjuvant Xelox chemotherapy prior to the operation, IHC was adopted to detect the expression of Tom1L1 protein in patients before and after neoadjuvant chemotherapy and to analyze the relationship between the expression level of Tom1L1 and the sensitivity of neoadjuvant therapy.

Results

The results of qPCR, Western blot and IHC showed that the expression of Tom1L1 in colorectal adenocarcinoma tissues was significantly higher than that in paracancerous normal tissues, with a statistically significant difference (P < 0.01); Neoadjuvant chemotherapy was significantly more effective in patients with low expression of Tom1L1 protein than in those with high expression of Tom1L1 protein, with a statistically significant difference (P < 0.05).

Conclusions

Tom1L1 is highly expressed in colorectal adenocarcinoma tissues; neoadjuvant Xelox chemotherapy can have an impact on Tom1L1 expression in progressive rectal cancer; patients with locally progressive mid-low rectal adenocarcinoma who have low Tom1L1 expression are more sensitive to neoadjuvant chemotherapy.

Yang Z, Jiang S, Lu C, Ji T, Yang W, Li T, Lv J, Hu W, Yang Y, Jin Z. SOX11: friend or foe in tumor prevention and carcinogenesis? Ther Adv Med Oncol. 2019;11:1758835919853449.PubMedPubMedCentralCrossRef

Hu W, Yang Y, Fan C, Ma Z, Deng C, Li T, Lv J, Yao W, Gao J. Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers. Apoptosis. 2016;21(6):675–82.PubMedCrossRef

Zhang X, Yu S, Li X, Wen X, Liu S, Zu R, Ren H, Li T, Yang C, Luo H. Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer? Pharmacol Res. 2023;191: 106777.PubMedCrossRef

Jokhadze N, Das A, Dizon DS. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024;74(3):224–6.PubMedCrossRef

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.PubMedCrossRef

Feng Y, Wang K, Fan J, Wu X, Li T, Yang Z. Mindfulness intervention, homogeneous medical concept, and concentrated solution nursing for colorectal cancer patients: a retrospective study. BMC Cancer. 2024;24(1):1055.PubMedPubMedCentralCrossRef

Wu X, Guan S, Lu Y, Xue J, Yu X, Zhang QI, Wang X, Li T. Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals. Oncol Res. 2023;31(2):125–39.PubMedPubMedCentralCrossRef

Niu Y, Xue J, Wu X, Qu M, Wang L, Liang W, Li T. Clinical Significance of Serum Haptoglobin and Protein Disulfide-Isomerase A3 in the Screening, Diagnosis, and Staging of Colorectal Cancer. Front Pharmacol. 2022;13: 935500.PubMedPubMedCentralCrossRef

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center. 2022;2(1):1–9.PubMedPubMedCentralCrossRef

10.

Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40(6):701–15.PubMedCrossRef

11.

Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651–7.PubMedPubMedCentralCrossRef

12.

Katoh M, Unakami M, Hara M, Fukuchi S. Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol. 1995;30(5):615–8.PubMedCrossRef

13.

Jimi S, Yasui T, Hotokezaka M, Shimada K, Shinagawa Y, Shiozaki H, Tsutsumi N, Takeda S. Clinical features and prognostic factors of bone metastases from colorectal cancer. Surg Today. 2013;43(7):751–6.PubMedCrossRef

14.

Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121(8):1195–203.PubMedCrossRef

15.

Christensen TD, Jensen SG, Larsen FO, Nielsen DL. Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer. J Bone Oncol. 2018;13:97–105.PubMedPubMedCentralCrossRef

16.

Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012;23(8):2072–7.PubMedCrossRef

17.

Shan L, Li T, Gu W, Gao Y, Zuo E, Qiu H, Li R, Cheng X. Application of Prognostic Models Based on Psoas Muscle Index, Stage, Pathological Grade, and Preoperative Carcinoembryonic Antigen Level in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy. J Oncol. 2022;2022:6851900.PubMedPubMedCentralCrossRef

18.

Wang L, Wu X, Xu W, Gao L, Wang X, Li T. Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer. Front Oncol. 2022;12: 713335.PubMedPubMedCentralCrossRef

19.

Sun M, Liu X, Xia L, Chen Y, Kuang L, Gu X, Li T. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. Biochem Pharmacol. 2021;189: 114285.PubMedCrossRef

20.

Martens MH, Maas M, Heijnen LA, Lambregts DM, Leijtens JW, Stassen LP, Breukink SO, Hoff C, Belgers EJ, Melenhorst J, et al. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer. J Natl Cancer. 2016;108(12):djw171.CrossRef

21.

Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int J Biol Sci. 2016;12(8):1022–31.PubMedPubMedCentralCrossRef

22.

Conde-Muíño R, Cuadros M, Zambudio N, Segura-Jiménez I, Cano C, Palma P. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. Biomed Res Int. 2015;2015: 921435.PubMedPubMedCentralCrossRef

23.

De Palma FDE, Luglio G, Tropeano FP, Pagano G, D’Armiento M, Kroemer G, Maiuri MC, De Palma GD. The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. Int J Mol Sci. 2020;21(19):7040.PubMedPubMedCentralCrossRef

24.

Schöneberg J, Lee IH, Iwasa JH, Hurley JH. Reverse-topology membrane scission by the ESCRT proteins. Nat Rev Mol Cell Biol. 2017;18(1):5–17.PubMedCrossRef

25.

Yanagida-Ishizaki Y, Takei T, Ishizaki R, Imakagura H, Takahashi S, Shin HW, Katoh Y, Nakayama K. Recruitment of Tom1L1/Srcasm to endosomes and the midbody by Tsg101. Cell Struct Funct. 2008;33(1):91–100.PubMedCrossRef

26.

Cabral-Dias R, Lucarelli S, Zak K, Rahmani S, Judge G, Abousawan J, DiGiovanni LF, Vural D, Anderson KE, Sugiyama MG, et al. Fyn and TOM1L1 are recruited to clathrin-coated pits and regulate Akt signaling. J Cell Biol. 2022;221(4):e201808181.PubMedPubMedCentralCrossRef

27.

Perry WRG. Abd El Aziz MA, Duchalais E, Grass F, Behm KT, Mathis KL, Kelley SR: Sexual dysfunction following surgery for rectal cancer: a single-institution experience. Updates Surg. 2021;73(6):2155–9.PubMedCrossRef

28.

Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef

29.

Carpinetti P, Donnard E, Bettoni F, Asprino P, Koyama F, Rozanski A, Sabbaga J, Habr-Gama A, Parmigiani RB, Galante PA, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–71.PubMedPubMedCentralCrossRef

30.

Kasi A, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, Sun W. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(12): e2030097.PubMedPubMedCentralCrossRef

31.

Yang IJ, Suh JW, Lee J, Ahn HM, Oh HK, Kim DW, Kim MJ, Ryoo SB, Jeong SY, Park KJ, et al. Comparison of tumor regression grade and clinical stage based on MRI image as a selection criterion for non-radical management after concurrent chemoradiotherapy in locally advanced rectal cancer: a multicenter, retrospective, cross-sectional study. Int J Colorectal Dis. 2022;37(7):1561–8.PubMedCrossRef

32.

Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, Strassburg J, Quirke P, Tekkis P, Pedersen BG, et al. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg. 2016;263(4):751–60.PubMedCrossRef

33.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv263.PubMedCrossRef

34.

Glynne-Jones R, Hughes R. Critical appraisal of the “wait and see” approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99(7):897–909.PubMedCrossRef

35.

36.

Dattani M, Heald RJ, Goussous G, Broadhurst J, São Julião GP, Habr-Gama A, Perez RO, Moran BJ. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. Ann Surg. 2018;268(6):955–67.PubMedCrossRef

37.

Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825–36.PubMedCrossRef

38.

Lu Z, Cheng P, Yang F, Zheng Z, Wang X. Long-term outcomes in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy and curative resection. Chin J Cancer Res. 2018;30(2):272–81.PubMedPubMedCentralCrossRef

39.

Zhang X, Ding R, Li J, Wu T, Shen Z, Li S, Zhang Y, Dong C, Shang Z, Zhou H, et al. Efficacy and safety of the “watch-and-wait” approach for rectal cancer with clinical complete response after neoadjuvant chemoradiotherapy: a meta-analysis. Surg Endosc. 2022;36(4):2233–44.PubMedCrossRef

40.

Georgescu MT, Patrascu T, Serbanescu LG, Anghel RM, Gales LN, Georgescu FT, Mitrica RI, Georgescu DE. When Should We Expect Curative Results of Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients? Chirurgia (Bucur). 2021;116(1):16–23.PubMedCrossRef

41.

Tranchart H, Lefèvre JH, Svrcek M, Flejou JF, Tiret E, Parc Y. What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? Ann Surg Oncol. 2013;20(5):1551–9.PubMedCrossRef

42.

Chiang JM, Hsieh PS, Chen JS, Tang R, You JF, Yeh CY. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy. World J Surg Oncol. 2014;12:197.PubMedPubMedCentralCrossRef

43.

Chevalier C, Roche S, Bénistant C. Vesicular trafficking regulators are new players in breast cancer progression: Role of TOM1L1 in ERBB2-dependent invasion. Mol Cell Oncol. 2016;3(4): e1182241.PubMedPubMedCentralCrossRef

44.

Chevalier C, Collin G, Descamps S, Touaitahuata H, Simon V, Reymond N, Fernandez L, Milhiet PE, Georget V, Urbach S, et al. TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion. Nat Commun. 2016;7:10765.PubMedPubMedCentralCrossRef

45.

Sirvent A, Vigy O, Orsetti B, Urbach S, Roche S. Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts. Mol Cell Proteomics. 2012;11(12):1937–50.PubMedPubMedCentralCrossRef

46.

Collin G, Franco M, Simon V, Bénistant C, Roche S. The Tom1L1-clathrin heavy chain complex regulates membrane partitioning of the tyrosine kinase Src required for mitogenic and transforming activities. Mol Cell Biol. 2007;27(21):7631–40.PubMedPubMedCentralCrossRef

47.

Lopes-Ramos CM, Habr-Gama A, Quevedo Bde S, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA, Gama-Rodrigues J, Camargo AA, et al. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics. 2014;7:68.PubMedPubMedCentralCrossRef

48.

Yamamichi N, Shimomura R, Inada K, Sakurai K, Haraguchi T, Ozaki Y, Fujita S, Mizutani T, Furukawa C, Fujishiro M, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res. 2009;15(12):4009–16.PubMedCrossRef

49.

Wu X, Yan F, Wang L, Sun G, Liu J, Qu M, Wang Y, Li T. MicroRNA: Another Pharmacological Avenue for Colorectal Cancer? Front Cell Dev Biol. 2020;8:812.PubMedPubMedCentralCrossRef

50.

Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–14.PubMedPubMedCentralCrossRef

51.

Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J, Sung JJ. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739–45.PubMedCrossRef

52.

Yu Y, Sarkar FH, Majumdar AP. Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens. Transl Oncol. 2013;6(2):180–6.PubMedPubMedCentralCrossRef

53.

Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015;113(1):83–90.PubMedPubMedCentralCrossRef

54.

Qi J, Zhang R, Wang Y. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1. J Cell Mol Med. 2021;25(23):11016–30.PubMedPubMedCentralCrossRef

55.

Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int J Mol Sci. 2017;18(3):573.PubMedPubMedCentralCrossRef

Title: Exploring the correlation between Tom1L1 and the efficacy of neoadjuvant chemotherapy for locally progressive mid-low rectal cancer
Authors: Meng Li
Zeyu Li
Xueliang Wu
Yubo Pan
Likun Wang
Jun Xue
Tian Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Rectal Cancer
Rectal Cancer
Cytostatic Therapy
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-13154-0

Breast cancer survivorship needs: a qualitative study

Open Access
Breast Cancer
Original Research

Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy

Open Access
Pancreatic Cancer
Original Research

Establishment of a risk prediction model for bowel preparation failure prior to colonoscopy

Open Access
Colonoscopy
Original Research

Selective anti-tumor activity of glutathione-responsive abasic site trapping agent in anaplastic thyroid carcinoma

Open Access
Original Research

Comparison of proximal gastrectomy and total gastrectomy in proximal gastric cancer: a meta-analysis of postoperative health condition using the PGSAS-45

Open Access
Gastrectomy
Original Research

Prognostic marker CD27 and its micro-environmental in multiple myeloma

Open Access
Multiple Myeloma
Original Research

Keynote series | Spotlight on menopause

Springer Medicine

Exploring the correlation between Tom1L1 and the efficacy of neoadjuvant chemotherapy for locally progressive mid-low rectal cancer

Unlock free access to practice-relevant journal articles

Looking for something specific?

About journals on Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content